In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections;Escherichia coli nedenli̇ kompli̇ke olmamiş üri̇ner si̇stem enfeksi̇yonlarinda fosfomi̇si̇n trometamolün i̇n vi̇tro etki̇nli̇ǧi̇

Mikrobiyoloji Bulteni

Volumn 43, Issue 4, 2009, Pages 645-649

  Hoşbul, Tuǧrul ^a   Özyurt, Mustafa ^a   Baylan, Orhan ^a   Bektöre, Bayhan ^a   Ardiç, Nurittin ^a   Ceylan, Süleyman ^b   Erdemoǧlu, Ali ^a   Haznedaroǧlu, Tunçer ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Escherichia coli; Fosfomycin trometamol; Urinary tract infection

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; FOSFOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIURIA; CHILD; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; INFANT; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIURIA; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 73149110167     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007;29:62-5.
2. Kepekçi P. Idrar kültürlerinden izole edilen Escherichia coli ve Klebsiella suşlarinda fosfomisin trometamol duyarliliǧi. T. C. Saǧlik Bakanhǧi Okmeydani Eǧitim ve Araştirma Hastanesi, Enfeksiyon Hastaliklari ve Klinik Mikrobiyoloji Kliniǧi, Uzmanlik Tezi, 2005.
3. Taşbakan Ml, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Toplum kökenli üriner sistem infeksiyonlanndan soyutlanan Escherichia coli suşłarina fosfomisinin in vitro etkinliǧinin diǧer antibiyotiklerle karşilaş tirlmasi. ANKEM 2004; 18:216-9.
4. Göker G, Kaya I, Aydin D, Gürler N. Üriner sistemden izole edilen Escherichia coli, Klebsiella ve enterokok cinsi bakterilerde fosfomisin duyarliliǧinin araştirilmasi. ANKEM 2007;21:219-22.
5. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997;53:637-56.
6. th ed. Churchill Livingstone, Toronto.
7. th Informational Supplement. CLSI Document M100-S18. 2008. CLSI, Pennsylvania.
8. Köken G, Aşik G, Çiftçi İH, Çetinkaya Z, Aktepe OC, Yilmazer M. Toplum kökenli üriner sistem infeksiyonu etkeni Escherichia coli suşlannda fosfomisin trometamol etkinliǧi. ANKEM 2008;22:23-7.
9. Mert D. Nonkomplike üriner infeksiyonlu hastalarda fosfomisin trometamol ve siprofloksasinin klinik etkinliǧinin karşilaş tirilrnasi. T. C. Saǧlik Bakanliǧi Haydarpaşa Numune Eǧitim ve Araştirma Hastanesi, Infeksiyon Hastahklari ve Klinik Mikrobiyoloji Kliniǧi, Uzmanlik Tezi, 2006.
10. Pullukçu H, Aydemir Ş, Taşbakan Ml, Cilli F, Tünger A, Ulusoy S. Susceptibility of extended-spectrum betalactamase-producing Escherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprimsulfamethoxazole. Turk J Med Sci 2008; 38:175-80.
11. Naber KG, Bergman B, Bishop MC, et al; Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001;40:576-88.
12. Kahlmeter G. The ECO. SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000; 46 (Suppl A) : 15-22.
13. Afşar I, Gönül B, Şener AG, Türker M. Escherichia coli" nin klinik izolatlannin fosfomisin trometamol ve diǧer antibiyotiklere in-vitro duyarhliǧi. ANKEM 2005;19:77-9.
14. Aykut Arca E, Karabiber N. Comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics. Mikrobiyol Bul 2007;41:115-9.
15. Arslan H, Azap OK, Ergönül O, Timurkaynak F; Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56:914-8.
16. Deveci O, Taskin SS, Kaygusuz S, Kilic D, Agalar C. Üriner sistem infeksiyonu etkeni E.coli suşlannda fosfomisin duyarliliǧinin araştirilmasi. Klimik Dergisi 2005; 18 (Özel Sayi) : 266.
17. Ko KS, Suh JY, Peck KR, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extendedspectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007;58:111-5.
18. Bonfiglio G, Mattina R, Lanzafame A, Cammarata E, Tempera G; Italian Medici Medicina Generale (MMG) Group. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy 2005;51:162-6.